Loading…
Based on limited metadata, Maitland Labs of Central Florida, a compounding pharmacy, received an FDA Warning Letter on August 6, 2021, regarding the production of adulterated drug products. The violations fall under pharmaceutical quality oversight and suggest issues with the compounding process, ingredient quality, or product safety standards. The warning was issued by the Office of Pharmaceutical Quality Operations, Division II, indicating the FDA's concern about systemic quality control deficiencies in the company's drug manufacturing practices.